1. China has unveiled a five-year plan (2026-30) to expand its pharmaceutical industry and accelerate development of frontier treatments, including gene editing, cell therapies, and AI-designed drugs [para. 1]. The blueprint, released by the Ministry of Industry and Information Technology and nine other government bodies, targets annual revenue above 3.5 trillion yuan ($520 billion) at major drugmakers by 2030, with annual growth exceeding 20% in the innovative-drug sector [para. 1][para. 2]. It also aims to produce at least five Chinese drug products with global annual sales surpassing $1 billion [para. 2]. This strategy underscores Beijing's push to turn pharmaceuticals into a strategic emerging industry and a new pillar of economic growth while helping domestic biotech firms compete globally [para. 3].
2. The sector has grown steadily under the previous plan, with value added by drug manufacturers expanding at a 4.1% average annual pace, accounting for roughly 3.6% of value added by major industrial companies [para. 4]. During that period, China approved 230 innovative drugs and 292 innovative medical devices, and its drug pipeline rose to second globally [para. 5].
3. The new plan sets ambitious targets: listed pharmaceutical companies are expected to raise R&D spending to over 10% of revenue on average [para. 6], and China aims to rank among global leaders in new drugs entering first clinical trials and reaching the market [para. 6]. First-in-class drugs, using new mechanisms of action, should account for more than 25% of the global total, with over 200 innovative medical devices approved by 2030 [para. 7]. The government also wants to cultivate 50 companies with annual revenue above 10 billion yuan and 20 industrial parks generating over 100 billion yuan yearly [para. 8].
4. The plan outlines 25 priority tasks across eight areas, focusing on original innovation and first-in-class drug development [para. 9]. It specifically supports fast-growing fields such as oligonucleotide therapies, PROTACs, molecular glues, bispecific antibodies, antibody-drug conjugates, radiopharmaceutical conjugates, CAR-T cell therapies, and induced pluripotent stem-cell treatments [para. 10]. In medical devices, priorities include implantable equipment, in vitro diagnostics, molecular diagnostics, single-cell sequencing, early cancer screening, genetic testing, high-end CT and MRI systems, AI-assisted diagnostics, radiotherapy systems, and surgical robots [para. 11][para. 12].
5. AI is central to the strategy, with plans to accelerate its use alongside quantum computing, supercomputing, and computational medicine in drug discovery [para. 13]. The plan encourages pharmaceutical companies to work with hospitals and research institutes to develop high-quality industry datasets and trusted health-data infrastructure, including specialized large language models and AI agents spanning drug discovery, clinical research, manufacturing optimization, and regulatory oversight [para. 14][para. 15]. Breakthrough targets also include gene editing, precision molecular delivery, cell programming, brain-computer interfaces, organoids, organs-on-chips, universal cell therapies, regenerative organs, and xenotransplantation [para. 14].
6. Six pharmaceutical industry clusters are identified for development: the Beijing-Tianjin-Hebei region, the Yangtze River Delta, the Guangdong-Hong Kong-Macao Greater Bay Area, the Chengdu-Chongqing region, a central China manufacturing cluster, and traditional Chinese and ethnic-medicine clusters in border regions [para. 17]. The plan also supports Chinese drugmakers seeking overseas growth through joint research and co-commercialization, while regulators align Chinese rules with international practices [para. 18].
7. Recent achievements show momentum: overseas licensing deals for Chinese innovative drugs exceeded $120 billion so far this year, up 36% year-on-year, with upfront payments topping $10 billion [para. 19]. China has approved 59 innovative drugs and 51 innovative medical devices this year, including 13 first-in-class drugs, and the world's first implantable brain-computer-interface system for hand-movement compensation reached the market [para. 20]. In 2025, over 2,900 new-drug clinical trials were registered, up 18%, while cell and gene therapy trials increased by roughly 30% [para. 21].
AI generated, for reference only
Sign in with Google
Sign in with Facebook
Sign in with 财新